Formoterol protects against platelet-activating factor-induced effects in asthma

European Respiratory Journal

Volumn 23, Issue 1, 2004, Pages 71-75

  Gabrijelcic, J ^a   Casas, A ^a   Rabinovich, R A ^a   Roca, J ^a   Barbera J A ^a   Chung, K F ^b   Rodriguez Rosin R ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airway obstruction; Bronchial challenge; Gas exchange; Inflammatory mediators; Long acting 2 agonists

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FORMOTEROL; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; THROMBOCYTE ACTIVATING FACTOR;

ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; FEMALE; FLUSHING; FORCED EXPIRATORY VOLUME; GAS EXCHANGE; HUMAN; IMMUNOPATHOGENESIS; LUNG BLOOD FLOW; LUNG RESISTANCE; LUNG VENTILATION PERFUSION RATIO; MALE; METERED DOSE INHALER; NEUTROPENIA; NEUTROPHILIA; PREDICTION; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ADULT; AIRWAY RESISTANCE; ASTHMA; COUGH; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSPNEA; ETHANOLAMINES; FEMALE; FLUSHING; HUMANS; MALE; NEUTROPENIA; PLATELET ACTIVATING FACTOR; PULMONARY CIRCULATION; PULMONARY GAS EXCHANGE; VENTILATION-PERFUSION RATIO;

EID: 0346505545     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00057803     Document Type: Article

References (30)

1. Chung KF. Platelet activating factor in inflammation and pulmonary disorders. Clin Sci 1992; 83: 127-138.
2. Rodriguez-Roisin R. Acute severe asthma: pathophysiology and pathobiology of gas exchange abnormalities. Eur Respir J 1997; 10: 1359-1371.
3. Rodriguez-Roisin R, Félez MA, Chung KF, et al. Platelet-activating factor causes ventilation-perfusion mismatch in humans. J Clin Invest 1994; 93: 188-194.
4. Félez MA, Roca J, Barberà JA, et al. Inhaled platelet activating factor worsens gas exchange in mild asthma. Am J Respir Crit Care Med 1994; 150: 369-373.
5. 4 release in stimulated alveolar macrophages from asthmatic patients. Eur Respir J 1998; 11: 1098-1104.
6. Echazarreta AL, Gómez F, Ribas J, et al. Effects of inhaled furosemide on platelet-activating factor challenge in mild asthma. Eur Respir J 1999; 14: 616-621.
7. Greiff L, Wollmer P, Andersson M, et al. Effects of formoterol on histamine induced plasma exudation in induced sputum from normal subjects. Thorax 1998; 53: 1010-1013.
8. 2-adrenergic agonists in COPD. Chest 2001; 120: 258-270.
9. Roca J, Félez MA, Chung KF, et al. Salbutamol inhibits pulmonary effects of platelet activating factor in man. Am J Respir Crit Care Med 1995; 151: 1740-1744.
10. Díaz O, Barberà JA, Marrades R, et al. Inhibition of PAF-induced gas exchange defects by beta-adrenergic agonists in mild asthma is not due to bronchodilatation. Am J Respir Crit Care Med 1997; 156: 17-22.
11. Spring J, Johnston SR, Seale J, et al. Failure of salmeterol to inhibit circulating white cell responses and bronchoconstriction induced by platelet activating factor. Thorax 1992; 47: 948-951.
12. Sulakvelidze I, McDonald DM. Anti-edema action of formoterol in rat trachea does not depend on capsaicin sensitive sensory nerves. Am J Respir Crit Care Med 1994; 149: 232-238.
13. Roca J, Wagner PD. Contributions of multiple inert gas elimination technique to pulmonary medicine: 1. Principles and information content of the multiple inert gas. Thorax 1994; 49: 815-824.
14. Glenny R, Wagner PD, Roca J, Rodriguez-Roisin R. Gas exchange in health: rest, exercise, and aging. In: Roca J, Rodríguez-Roisin R, Wagner PD, eds. Pulmonary and peripheral gas exchange in health and disease. New York, Marcel Dekker Inc., 2000: pp. 121-148.
15. Acuña AA, Gabrijelcic J, Uribe EM, et al. Fluticasone propionate attenuates PAF-induced gas exchange defects in mild asthma. Eur Respir J 2002; 19: 872-878.
16. 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am J Physiol 1994; 266: 461-468.
17. Chung KF, Barnes PJ. Effects of platelet-activating factor on airway calibre, airway responsiveness, and circulating cells in asthmatic subjects. Thorax 1989; 44: 108-115.
18. Erjefalt I, Persson CG. Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. Am Rev Respir Dis 1991; 144: 788-791.
19. Bolton PB, Lefevre P, McDonald DM. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 1997; 155: 1428-1435.
20. 2-adrenergic agonist formoterol. J Appl Physiol 1994; 77: 397-405.
21. 4 expression. Eur Respir J 2003; 22: 290-297.
22. Boschetto P, Roberts NM, Rogers DF, et al. The effect of anti-asthma drugs on microvascular leak in guinea pig airways. Am Rev Respir Dis 1988; 139: 416-421.
23. Wort SJ, Shakur BH, Ind P. Formoterol protects against the neutropenia induced by platelet activating factor in humans (abstract). Eur Respir J 1998; 12: Suppl. 28, 323s.
24. Anderson R, Feldman C, Theron AJ, et al. Anti-inflammatory membrane-stabilizing interactions of salmeterol with human neutrophils in vitro. Br J Pharmacol 1996; 117: 1387-1394.
25. Politiek MJ, Boorsma A, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999; 13: 988-992.
26. 2-adrenoceptor agonist on platelet-activating factor-induced airway microvascular leakage and bronchoconstriction in the guinea pig. Agents Actions 1993; 40: 50-56.
27. Whelan CJ, Johnson M, Vardley CJ. Comparison of the anti-inflammatory properties of formoterol, salbutamol and salmeterol in guinea-pig skin and lung. Br J Pharmacol 1993; 110: 613-618.
28. Jeffery PK, Venge P, Gizycki MJ, et al. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 2002; 20: 1378-1385.
29. Malolepszy J, Böszörményi Nagy G, Selroos O, et al. Safety of formoterol Turbuhaler® at cumulative dose of 90 μg in patients with acute bronchial obstruction. Eur Respir J 2001; 18: 928-934.
30. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.